HER2-positive Breast Cancer Clinical Trials in Nashville, Tennessee

5 studies are recruiting for her2-positive breast cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. A Phase 1/1b Study of IAM1363 in HER2 Cancers

   This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   53 in total

   Run by

   Iambic Therapeutics, Inc

   See if you can join NCT06253871 on ClinicalTrials.gov

3. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

   The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (Nashville), Nashville, Tennessee

   Locations

   35 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT07102381 on ClinicalTrials.gov

4. ATEMPT 2.0: Adjuvant T-DM1 vs TH

   This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Greco-Hainsworth Centers for Research/Tennessee Oncology, Nashville, Tennessee

   Locations

   53 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04893109 on ClinicalTrials.gov

5. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

   The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   42 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT01042379 on ClinicalTrials.gov